|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
2-adrenoceptor exhibits blunted desensitization of cardiac functional responses in vivo
1 Departments of Pathophysiology and Nephrology, University of Essen Medical School, Essen, Germany; Institute of Pharmacology, Martin-Luther-University of Halle, Halle, Germany
2 Department of Anesthesiology, Martin-Luther-University of Halle, Halle, Germany
3 Departments of Pathophysiology and Nephrology, University of Essen Medical School, Essen, Germany
* To whom correspondence should be addressed. E-mail: otto-erich.brodde{at}uni-essen.de.
In subjects heterozygous for the Thr164Ile
2 -adrenoceptor (
2AR) polymorphism cardiac responses to
2AR-agonist stimulation are blunted.
In this study we investigated agonist-induced desensitization of the Thr164Ile
2AR. For this purpose we assessed in 6 subjects heterozygous Thr164Ile and in 10 subjects homozygous wild-type (WT)
2AR the effects of two weeks oral treatment with 3x5mg/ day terbutaline (TER) on TER-infusion induced increases in heart rate (HR) and contractility (measured as shortening of HR-corrected duration of electromechanical systole, QS2c).
Compared to WT
2AR subjects, Thr164Ile subjects exhibited a blunted TER-induced maximum increase in HR (WT 32±4 bpm, Thr164Ile 19±3 bpm; p<0.05) and contractility (WT -54±2 ms, Thr164Ile -37±6 ms; p<0.05). Two weeks oral TER-treatment desensitized cardiac
2AR responses to TER-infusion (increase in HR WT: 10±2, Thr164Ile: 8±4 bpm; in contractility WT: -22±5, Thr164Ile: -17±6 ms); however, the extent in desensitization was larger in WT than in Thr164Ile
2AR subjects. Thus, after 2 weeks oral TER-treatment cardiac
2AR responses did not differ anymore between WT and Thr164Ile
2AR subjects.
We conclude that agonist-induced desensitization of cardiac
2AR is more pronounced in WT than in Thr164Ile subjects. Thus, cardiac Thr164Ile appear to be somewhat protected against agonist-induced desensitization.
This article has been cited by other articles:
![]() |
D. Rosskopf and M. C. Michel Pharmacogenomics of G Protein-Coupled Receptor Ligands in Cardiovascular Medicine Pharmacol. Rev., December 1, 2008; 60(4): 513 - 535. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Barbato, M. Penicka, L. Delrue, F. Van Durme, B. De Bruyne, M. Goethals, W. Wijns, M. Vanderheyden, and J. Bartunek Thr164Ile polymorphism of {beta}2-adrenergic receptor negatively modulates cardiac contractility: implications for prognosis in patients with idiopathic dilated cardiomyopathy Heart, July 1, 2007; 93(7): 856 - 861. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Visit Other APS Journals Online |